SHARE NOW
Cell and gene therapy CDMO partner adthera bio has announced its break from stealth with funding from Delin Ventures, and unveils an experienced leadership team and new cutting-edge facilities.
The Company’s multi-site, highly-digital and integrated approaches, aim to bring highly tailored solutions to clients featuring optimized quality and reduced timelines.
As it comes out of stealth, adthera shares its purpose-built, state-of-the-art process development and analytical laboratory facilities, as well as a separate GMP production unit, based in London and Birmingham, UK.
The Company has also built a mock clean suite for training and process refinement before products will enter a GMP suite for production. This aims to maximize success and minimize risks, hurdles, and costs incurred by process flaws very early on.
Manufacturing is to be validated at adthera headquarters before being transferred and scaled into its distributed GMP network, that plans to be expand into multiple sites in multiple countries.
“We have built state of the art laboratories with all the latest technology enabling us to truly partnerand tailor processes to give an exceptional level of support to our projects. We even have the first Miltenyi Biotec Prodigy integrated workstations in the UK and our purpose built, platform agnostic suite is cutting edge for our partners to come and see for themselves,” comments Stuart Curbishley, Chief Development and Manufacturing Officer.
How are you enjoying this news article? Let us know your thoughts, here >>
Colin Sims, adthera CEO comments, ‘it is a privilege to be part of such an outstanding team whose mission is to bring more of these amazing ATMP treatments to patients who urgently need them. We have experts at board level helping us shape and define new precedents in go-to-market, development and regulatory frameworks”.
Combined, the team at adthera bring over 100 years of experience working in the cell and gene therapy advanced therapy medicinal products (ATMPs) space. With experience gained from public institutions like the SNBTS (Scottish National Blood Transfusion Service) and academic centres of excellence alongside existing blue-chip names like GSK, Novartis, Sanofi, Miltenyi Biotec and managerial planning support like BCG and Accenture.
The Board of Directors includes leading industry experts like Hilary Malone the former Chief Regulatory Officer at Sanofi and biotech c-suite, and Carol Lynch, former Chief Business Officer at Sandoz and Delin Ventures Board Member.
“We really have a hand-picked team of the best talent in the field, in wonderful new facilities with the latest equipment, training and thinking. Partnering with us will be a transparent and exciting journey relentlessly focused on delivering high quality products for patients. Our deep understanding of technology to produce ATMPs will benefit all our partners, regardless of disease target or therapeutic approach,” adds John Campbell, Chief Scientific Officer.
Source: adthera Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
